Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Market Size By Type (CEL-1000, D-3252), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

lobal Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Report Description

The Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market was valued at USD 2.3 billion in 2023 and is projected to surpass USD 4.8 billion by 2031, growing at a CAGR of 9.5% during the forecast period (2023-2031).

The market growth is driven by the increasing awareness of pandemic preparedness, advancements in antiviral drug development, and rising investments in infectious disease research. Since the SARS outbreak in 2003 and subsequent concerns over COVID-like coronaviruses, there has been a significant push for the development of broad-spectrum antivirals, monoclonal antibodies, and immunomodulators.

The rise of global infectious disease surveillance programs and strong government funding in infectious disease research are further catalyzing the demand for SARS-targeted and coronavirus-related therapeutics.

Drivers

Growing Threat of Emerging Infectious Diseases

The increasing risk of SARS-like coronavirus outbreaks has accelerated R&D in therapeutic solutions, including antivirals, monoclonal antibodies, and immune-boosting therapies.

Government and Institutional Funding

Global health agencies and governments are heavily investing in SARS and coronavirus-related research to strengthen healthcare resilience against future outbreaks.

Advancements in Biotechnology and Drug Development

Cutting-edge technologies like mRNA platforms, CRISPR-based diagnostics, and AI-driven drug discovery are expediting the development of effective SARS therapeutics.

Restraints

High Development and Regulatory Costs

Developing antiviral drugs and monoclonal antibodies is expensive and time-consuming, with stringent regulatory requirements for safety and efficacy.

Limited Market in Post-Outbreak Phases

Demand for SARS therapeutics may decline during non-pandemic periods, affecting the long-term profitability for pharmaceutical companies.

Opportunities

Broad-Spectrum Coronavirus Therapeutics

Companies developing therapies that target multiple coronavirus strains (SARS-CoV, SARS-CoV-2, MERS-CoV) have significant future opportunities.

Emerging Markets & Stockpiling Programs

Governments in Asia-Pacific, the Middle East, and Africa are increasingly stockpiling antiviral therapeutics, creating a strong growth opportunity.

Combination Therapies and Immunomodulators

Expanding research in synergistic drug combinations and immunotherapies can open new market segments.

Market by System Type Insights

Based on therapeutic class:

Antiviral Drugs accounted for the largest market share in 2023, driven by the success of repurposed antiviral molecules and new drug launches.

Monoclonal Antibodies are expected to witness the highest growth rate, owing to their targeted mechanism and rising demand for precision medicine in infectious diseases.

Market by End-use Insights

By end-use:

Hospitals & Clinics dominated the market in 2023, as they remain the primary treatment centers during outbreaks.

Government Stockpiles & Emergency Centers are expected to grow significantly due to global pandemic preparedness programs.

Market by Regional Insights

North America led the global SARS therapeutics market in 2023, supported by strong pharmaceutical R&D infrastructure and government funding.

Asia-Pacific is expected to grow at the fastest CAGR, driven by prior outbreak experiences, large populations, and expanding healthcare investments in China, Singapore, and South Korea.

Europe holds a substantial market share due to well-established infectious disease research networks.

Competitive Scenario

Key players in the Global SARS Therapeutics Market include Gilead Sciences, Roche, Pfizer, Regeneron Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Moderna Therapeutics, Merck & Co., AstraZeneca, and Sanofi.

In 2024, Gilead announced new clinical trials for broad-spectrum coronavirus antivirals.

Pfizer launched a next-generation protease inhibitor in 2023 with enhanced efficacy against SARS-like viruses.

Moderna expanded its mRNA-based therapeutic pipeline targeting emerging coronavirus variants.

Scope of Work – Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market

Key Market Developments

March 2024: Regeneron Pharmaceuticals announced the approval of a new monoclonal antibody with cross-protection for multiple SARS-like coronaviruses.

January 2024: Gilead Sciences expanded its antiviral portfolio with a new oral therapeutic for SARS-CoV variants.

July 2023: Moderna launched early-stage trials for an mRNA-based combination therapeutic for SARS-CoV and MERS-CoV.

FAQs

1. What is the current market size of the Global SARS Therapeutics Market?

The market was valued at USD 2.3 billion in 2023.

2. What is the major growth driver of the SARS Therapeutics Market?

The primary driver is the increasing need for pandemic preparedness and advancements in antiviral drug development.

3. Which is the largest region during the forecast period in the SARS Therapeutics Market?

North America is expected to remain the largest market due to strong R&D infrastructure and government funding.

4. Which segment accounted for the largest market share in SARS Therapeutics Market?

The Antiviral Drugs segment held the largest share in 2023.

5. Who are the key market players in the SARS Therapeutics Market?

Key players include Gilead Sciences, Pfizer, Roche, Regeneron, Moderna, and AstraZeneca.

Would you like me to create a downloadable Word document with this structured report for easy sharing and formatting?